Flagship Pioneering, a Cambridge, US-based venture capital group, is to explore the potential for drug discovery of a new approach to cell biology under a collaboration with Pfizer Inc and tapping the scientific expertise of Quotient Therapeutics Ltd, a biotech it founded in 2022. Located in Cambridge, UK, Quotient is investigating somatic genomics which describes alterations in DNA among individuals, or differences in DNA between populations among the same species.
